An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation

Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilinski, Pretoria, Webb, Myles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596197/
https://www.ncbi.nlm.nih.gov/pubmed/33145175
http://dx.doi.org/10.1016/j.eucr.2020.101467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596197/
https://www.ncbi.nlm.nih.gov/pubmed/33145175
http://dx.doi.org/10.1016/j.eucr.2020.101467

Ejemplares similares